TISIDB

Summary
Symbol	PKD2L1
Name	polycystic kidney disease 2-like 1
Aliases	TRPP3; transient receptor potential cation channel, subfamily P, member 3; PKD2L; PKDL; polycystin-2 homolog ......
Chromosomal Location	10q24.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell projection, cilium membrane; Multi-pass membrane protein. Cell membrane; Multi-pass membrane protein. Endoplasmic reticulum Note=Interaction with PKD1 or PKD1L3 is required for localization to the cell membrane.
Domain	PF08016 Polycystin cation channel
Function	Pore-forming subunit of a ciliary calcium channel that controls calcium concentration within primary cilia without affecting cytoplasmic calcium concentration. Forms a heterodimer with PKD1L1 in primary cilia and forms a calcium-permeant ciliary channel that regulates sonic hedgehog/SHH signaling and GLI2 transcription. May act as a sour taste receptor by forming a calcium channel with PKD1L3 in gustatory cells; however, its contribution to sour taste perception is unclear in vivo and may be indirect.

> Gene Ontology [ TOP ]
Biological Process	GO:0001581 detection of chemical stimulus involved in sensory perception of sour taste GO:0006813 potassium ion transport GO:0006814 sodium ion transport GO:0006816 calcium ion transport GO:0007224 smoothened signaling pathway GO:0009268 response to pH GO:0009581 detection of external stimulus GO:0009582 detection of abiotic stimulus GO:0009612 response to mechanical stimulus GO:0010447 response to acidic pH GO:0015672 monovalent inorganic cation transport GO:0035725 sodium ion transmembrane transport GO:0050907 detection of chemical stimulus involved in sensory perception GO:0050909 sensory perception of taste GO:0050912 detection of chemical stimulus involved in sensory perception of taste GO:0050915 sensory perception of sour taste GO:0050982 detection of mechanical stimulus GO:0051259 protein oligomerization GO:0051260 protein homooligomerization GO:0070206 protein trimerization GO:0070207 protein homotrimerization GO:0070588 calcium ion transmembrane transport GO:0070838 divalent metal ion transport GO:0071214 cellular response to abiotic stimulus GO:0071467 cellular response to pH GO:0071468 cellular response to acidic pH GO:0071804 cellular potassium ion transport GO:0071805 potassium ion transmembrane transport GO:0072511 divalent inorganic cation transport
Molecular Function	GO:0005216 ion channel activity GO:0005227 calcium activated cation channel activity GO:0005261 cation channel activity GO:0005262 calcium channel activity GO:0005267 potassium channel activity GO:0005272 sodium channel activity GO:0008527 taste receptor activity GO:0015077 monovalent inorganic cation transmembrane transporter activity GO:0015079 potassium ion transmembrane transporter activity GO:0015081 sodium ion transmembrane transporter activity GO:0015085 calcium ion transmembrane transporter activity GO:0015267 channel activity GO:0015269 calcium-activated potassium channel activity GO:0022803 passive transmembrane transporter activity GO:0022836 gated channel activity GO:0022838 substrate-specific channel activity GO:0022839 ion gated channel activity GO:0033040 sour taste receptor activity GO:0042805 actinin binding GO:0046873 metal ion transmembrane transporter activity GO:0051371 muscle alpha-actinin binding GO:0051393 alpha-actinin binding GO:0072509 divalent inorganic cation transmembrane transporter activity
Cellular Component	GO:0005929 cilium GO:0031253 cell projection membrane GO:0031513 nonmotile primary cilium GO:0034702 ion channel complex GO:0034703 cation channel complex GO:0034704 calcium channel complex GO:0043235 receptor complex GO:0044441 ciliary part GO:0060170 ciliary membrane GO:0072372 primary cilium GO:1902495 transmembrane transporter complex GO:1990351 transporter complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04742 Taste transduction
Reactome	-

Summary
Symbol	PKD2L1
Name	polycystic kidney disease 2-like 1
Aliases	TRPP3; transient receptor potential cation channel, subfamily P, member 3; PKD2L; PKDL; polycystin-2 homolog ......
Chromosomal Location	10q24.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between PKD2L1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	PKD2L1
Name	polycystic kidney disease 2-like 1
Aliases	TRPP3; transient receptor potential cation channel, subfamily P, member 3; PKD2L; PKDL; polycystin-2 homolog ......
Chromosomal Location	10q24.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of PKD2L1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	PKD2L1
Name	polycystic kidney disease 2-like 1
Aliases	TRPP3; transient receptor potential cation channel, subfamily P, member 3; PKD2L; PKDL; polycystin-2 homolog ......
Chromosomal Location	10q24.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of PKD2L1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0	1
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0	1
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0	1
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.902	0.188
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-1.008	0.389
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.768	0.569
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.429	0.541
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	1.292	0.202
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.521	0.628
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.259	0.115
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.302	0.226
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.661	0.00441

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of PKD2L1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	11.8	-11.8	0.488
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	33.3	-33.3	0.231
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	7.1	-7.1	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	7.4	-2.1	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	7.7	-7.7	0.371
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	12.5	7.1	5.4	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	PKD2L1
Name	polycystic kidney disease 2-like 1
Aliases	TRPP3; transient receptor potential cation channel, subfamily P, member 3; PKD2L; PKDL; polycystin-2 homolog ......
Chromosomal Location	10q24.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PKD2L1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	PKD2L1
Name	polycystic kidney disease 2-like 1
Aliases	TRPP3; transient receptor potential cation channel, subfamily P, member 3; PKD2L; PKDL; polycystin-2 homolog ......
Chromosomal Location	10q24.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PKD2L1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PKD2L1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	PKD2L1
Name	polycystic kidney disease 2-like 1
Aliases	TRPP3; transient receptor potential cation channel, subfamily P, member 3; PKD2L; PKDL; polycystin-2 homolog ......
Chromosomal Location	10q24.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PKD2L1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	PKD2L1
Name	polycystic kidney disease 2-like 1
Aliases	TRPP3; transient receptor potential cation channel, subfamily P, member 3; PKD2L; PKDL; polycystin-2 homolog ......
Chromosomal Location	10q24.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of PKD2L1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	PKD2L1
Name	polycystic kidney disease 2-like 1
Aliases	TRPP3; transient receptor potential cation channel, subfamily P, member 3; PKD2L; PKDL; polycystin-2 homolog ......
Chromosomal Location	10q24.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between PKD2L1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	PKD2L1
Name	polycystic kidney disease 2-like 1
Aliases	TRPP3; transient receptor potential cation channel, subfamily P, member 3; PKD2L; PKDL; polycystin-2 homolog ......
Chromosomal Location	10q24.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting PKD2L1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse PKD2L1